Skip to main content

Table 1 Characteristics of the study patients and controls

From: Isolation and Quantification of Blood Apoptotic Bodies, a Non-invasive Tool to Evaluate Apoptosis in Patients with Ischemic Stroke and Neurodegenerative Diseases

Subject code

Neurological disease

Gender

Age

Clinical features at time of blood collection

IS1

Ischemic stroke

Male

82

Acute phase (undetermined etiology), occlusion of left cerebral artery, affected cerebral volume: 57,835 cm3

IS2

Ischemic stroke

Female

55

Acute phase (undetermined etiology), occlusion of right cerebral artery, affected cerebral volume: 45,080 cm3

IS3

Ischemic stroke

Male

57

Acute phase (cardioembolic etiology), occlusion of right cerebral artery, affected cerebral volume: 36,980 cm3

IS4

Ischemic stroke

Male

64

Acute phase (cardioembolic etiology), occlusion of right cerebral artery, affected cerebral volume: 65,605 cm3

MS1

Multiple sclerosis

Female

37

Relapse episode (early RRMSa type)

MS2

Multiple sclerosis

Female

27

Relapse episode (early RRMS type)

MS3

Multiple sclerosis

Male

34

Relapse episode (early RRMS type)

MS4

Multiple sclerosis

Female

24

Relapse episode (early RRMS type)

PD1

Parkinson’s disease

Female

65

H&Yb stage II (tremor-dominant type)

PD2

Parkinson’s disease

Female

62

H&Y stage II (tremor-dominant type)

PD3

Parkinson’s disease

Female

71

H&Y stage II (akinetic-rigid type)

PD4

Parkinson’s disease

Male

75

H&Y stage II (akinetic-rigid type)

H1

Control

Male

66

Healthy volunteer

H2

Control

Female

75

Healthy volunteer

H3

Control

Male

82

Healthy volunteer

H4

Control

Female

62

Healthy volunteer

H5

Control

Female

27

Healthy volunteer

H6

Control

Male

36

Healthy volunteer

  1. Subject code, neurological disease, gender, age, clinical features at time of blood collection are shown. aRRMS relapsing-remitting multiple sclerosis. bH&Y Hoehn and Yahr scale
  2. Blood samples of isquemic patients were obtained within 5 h after symptom onset
  3. Blood extractions of patients with multiple sclerosis was carried out during the first manifestation, while those of patients with Parkinson’s diseases were performed after 7–12 years after diagnosis